c19early.org COVID-19 treatment researchCannabidiolCannabidiol (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
 
More

Supplementary Data — Cannabidiol for COVID-19: real-time meta analysis of 8 studies

@CovidAnalysis, December 2024, Version 18V18
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Crippa (DB RCT) -557% 6.57 [0.35-124] hosp. 3/49 0/42 Improvement, RR [CI] Treatment Control Crippa (DB RCT) -33% 1.33 [0.86-2.08] recov. time 49 (n) 42 (n) Nguyen 50% 0.50 [0.31-0.82] cases 26/531 48/531 Nguyen 33% 0.67 [0.49-0.91] cases 75/1,212 108/1,212 Huang -181% 2.81 [1.04-7.58] death 13,099 (all patients) Huang 19% 0.81 [0.73-0.90] cases 13,099 (all patients) Merianos -212% 3.12 [1.87-4.97] symp. case 94/416 20/384 Merianos -71% 1.71 [1.13-2.49] symp. case 77/416 38/384 Merianos -3% 1.03 [0.96-1.09] cases 367/416 317/384 Lehrer -24% 1.24 [1.05-1.45] cases n/a n/a Shover (PSM) 2% 0.98 [0.94-1.04] death 3/69 199/1,762 Shover (PSM) 5% 0.95 [0.91-0.99] ventilation 3/69 292/1,762 Shover (PSM) 9% 0.91 [0.85-0.99] ICU 8/69 543/1,762 Shover 3% 0.97 [0.92-1.02] oxygen 35/69 1,417/1,762 Mannumbet.. (PSM) 56% 0.44 [0.35-0.56] death Mannumbet.. (PSM) 25% 0.75 [0.70-0.81] ventilation Mannumbet.. (PSM) -6% 1.06 [1.02-1.10] hosp. time Griffith 3% 0.97 [0.82-1.14] death Griffith -27% 1.27 [1.14-1.41] ICU Griffith -80% 1.80 [1.68-1.93] hosp. Cannabidiol COVID-19 outcomes c19early.org December 2024 Favors cannabidiol Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit